Abstract:
BACKGROUND:Psoriasis is a chronic autoimmune disease characterized by infiltration of the dermis and epidermis by activated T cells and the hyperproliferation and abnormal differentiation of keratinocytes. It is a life-long disease with alternating periods of remission and recurrence. Efalizumab is a humanized, recombinant, T-cell targeting monoclonal antibody, approved for use in adults with chronic moderate to severe plaque psoriasis. OBJECTIVE:To assess the safety of continued or newly initiated treatment with efalizumab for up to 48 weeks in patients with psoriasis who were treated previously with efalizumab or placebo. METHODS:This study was an open-label, 48-week extension of a previously published 12-week, randomized, double-blind, parallel-group, placebo-controlled, multicentre, phase IIIb study, carried out in the US and Canada between 24 October 2002 and 2 July 2004. Patients were followed and treated at the study clinic in an outpatient setting and also were trained to self-administer the drug at home. Patients comprising individuals with chronic moderate to severe plaque psoriasis who had completed the 12-week, placebo-controlled segment of the study were eligible for enrolment in the extension phase. Of the 686 patients enrolled in the study, 636 (92.7%) enrolled in the open-label extension of the study, 418 of whom had received 12 weeks of efalizumab therapy and 218 of whom had received 12 weeks of placebo. All patients entering the open-label phase of the study received efalizumab 1 mg/kg/wk for an additional 48 weeks, for a maximum exposure of up to 60 weeks. Safety was evaluated by an assessment of adverse events, including infections and serious adverse events. RESULTS:The rate of withdrawal due to adverse events remained low throughout the trial, ranging from 1.2% to 6.6% during the 12-week segments of the open-label extension phase of the trial. The incidence of adverse events decreased with increased exposure to efalizumab; the incidence during the initial 12 weeks of exposure to efalizumab was 79.0% compared with 72.9% for patients exposed to placebo. Patients treated with efalizumab for 13-24 weeks, 25-36 weeks, 37-48 weeks and 49-60 weeks experienced adverse events at an incidence of 66.8%, 54.3%, 49.6% and 48.5%, respectively. The incidence of serious adverse events ranged from 1.6% to 3.5% during the 12-week segments of efalizumab therapy, compared with an incidence of 3.4% for placebo-treated patients. The incidence of infection ranged from 9.9% to 14.7% during the 12-week segments of efalizumab therapy, compared with an incidence of 19.1% for placebo-treated patients. Malignancies were reported with an incidence of =1.0% for efalizumab-treated patients during any 12-week segment compared with 0.4% for the 12-week placebo-treated patients. Of the 15 malignancies reported for efalizumab-treated patients, 13 were basal cell (n = 4) or squamous cell (n = 9) carcinomas. CONCLUSIONS:These results support the short-term safety profile demonstrated for efalizumab over a longer-term therapy period of up to 60 weeks.
journal_name
Drug Safjournal_title
Drug safetyauthors
Hamilton T,Menter A,Caro I,Compton P,Sobell J,Papp KAdoi
10.2165/00002018-200831080-00008subject
Has Abstractpub_date
2008-01-01 00:00:00pages
715-26issue
8eissn
0114-5916issn
1179-1942pii
3188journal_volume
31pub_type
杂志文章,随机对照试验相关文献
DRUG SAFETY文献大全abstract:BACKGROUND:Several efforts are under way to develop and test methods for prospective drug safety monitoring using large, electronic claims databases. Prospective monitoring systems must incorporate signalling algorithms and techniques to mitigate confounding in order to minimize false positive and false negative signal...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.2165/11594770-000000000-00000
更新日期:2012-05-01 00:00:00
abstract::Drug eruptions are among the most common adverse drug reactions, affecting approximately 3% of hospitalised patients. Although the rate of severe cutaneous adverse reactions to medications is low, these reactions can affect anyone who takes medication, and can result in death or disability. Two general patterns can be...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.2165/00002018-200730110-00003
更新日期:2007-01-01 00:00:00
abstract:BACKGROUND:Automated disproportionality analysis of spontaneous reporting is increasingly used routinely. It can theoretically be influenced by a competition bias for signal detection owing to the presence of reports related to well-established drug-event associations. OBJECTIVE:The aim of the study was to explore the...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.1007/BF03261981
更新日期:2012-10-01 00:00:00
abstract:INTRODUCTION:Non-steroidal anti-inflammatory drugs are associated with a dose and duration-dependent coronary risk. There is little information concerning analgesic-dose ibuprofen, among the most widely used drugs worldwide. OBJECTIVE:Our objective was to measure the risks of acute coronary syndrome (ACS) after dispen...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.1007/s40264-018-0686-7
更新日期:2018-11-01 00:00:00
abstract::Human papillomavirus (HPV) vaccines are now included in immunisation programmes in 71 countries. Unfortunately, uptake has been impacted in some countries by reduced confidence in the safety of the HPV vaccine. In 2013, we published an extensive review demonstrating a reassuring safety profile for bivalent (2vHPV) and...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.1007/s40264-017-0625-z
更新日期:2018-04-01 00:00:00
abstract:INTRODUCTION:Pharmacovigilance, the monitoring of drug safety after marketing approval, highly depends on the adequate reporting of adverse drug reactions (ADRs). To improve pharmacovigilance awareness and future ADR reporting among medical students, we developed and evaluated a student-run pharmacovigilance programme....
journal_title:Drug safety
pub_type: 杂志文章
doi:10.1007/s40264-016-0502-1
更新日期:2017-05-01 00:00:00
abstract::The biochemistry of vitamin K metabolism and the role of vitamin K-dependent gamma-carboxylation of the vitamin K-dependent coagulation factors are now well understood. Likewise, there is a clear understanding of the role of oral anticoagulants in the inhibition of these coagulation factors. However, the effect of ora...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.2165/00002018-199309040-00004
更新日期:1993-10-01 00:00:00
abstract:BACKGROUND:Rituximab is a monoclonal antibody approved for treating CD20-positive B-cell non-Hodgkin's lymphoma and rheumatoid arthritis but is used off-label for treating many autoimmune disorders, including multiple sclerosis (MS). Similarly to other monoclonal antibodies, the incidence of infusion-related reactions ...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.2165/11585960-000000000-00000
更新日期:2011-02-01 00:00:00
abstract::Two Japanese regulatory agencies, the Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency announced the implementation of a new review system called 'Conditional Approval,' specifically for the emerging field of regenerative medicine, in an amendment to the Pharmaceutical Affairs ...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.1007/s40264-017-0517-2
更新日期:2017-06-01 00:00:00
abstract:OBJECTIVES:A prescription event monitoring (PEM) postmarketing surveillance study was carried out to examine the safety of zafirlukast as used in general practice in England. METHODS:Exposure data were obtained from the first National Health Service (NHS) prescription dispensed for patients whose prescription details ...
journal_title:Drug safety
pub_type: 临床试验,杂志文章
doi:10.2165/00002018-200730050-00005
更新日期:2007-01-01 00:00:00
abstract::The last decade has seen an increase in the trend of HMG-CoA reductase inhibitor (statin) usage in the Western world, which does not come as a surprise noting that the latest American Heart Association heart and stroke statistics indicate an alarming prevalence of 80 million Americans (one in three) with one or more ...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.2165/11584380-000000000-00000
更新日期:2011-01-01 00:00:00
abstract::The increasing incidence of Crohn's disease has lead to speculation about changes in exposures to environmental or infectious agents. Considerable attention has focused on the role of measles infection and/or vaccination in the pathogenesis of Crohn's disease and ulcerative colitis. Current evidence regarding the asso...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.2165/00002018-200124130-00001
更新日期:2001-01-01 00:00:00
abstract::Pelargonium (Pelargonium sidoides DC and P. reniforme Curtis) is reported to have immune modulating properties and antibacterial activity, and Pelargonium extracts have been used for the treatment of respiratory tract and gastrointestinal infections. Introduced in the early 1980s in Germany, Umckaloabo (ISO Arzneimitt...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.2165/00002018-200730080-00004
更新日期:2007-01-01 00:00:00
abstract::Current antiretroviral therapy has lead to longer survival in patients infected with HIV, but it is also associated with new and important problems. Body fat redistribution and metabolic abnormalities, the so-called lipodystrophy syndrome, are among the most prevalent and worrisome ones. While an increasing number of ...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.2165/00002018-200124030-00001
更新日期:2001-01-01 00:00:00
abstract::Women who discover they are pregnant after exposure to a drug and pregnant women who have a condition that requires continued treatment during pregnancy are told to balance the benefits and risks of the exposure to justify continuation of treatment, discontinuation of treatment or, possibly, pregnancy termination. How...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.2165/00002018-200427060-00001
更新日期:2004-01-01 00:00:00
abstract::Childhood hyperactivity is a common behavioural complaint. The therapeutic options for physicians caring for children with hyperactivity are considerable and varied; current recommendations call for a multidisciplinary approach, including when necessary the use of drug therapy. Central nervous system stimulants are th...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.2165/00002018-199309010-00004
更新日期:1993-07-01 00:00:00
abstract:BACKGROUND:Spontaneous reports of suspected adverse drug reactions to regulatory bodies and market authorization holders are important in pharmacovigilance. Follow-up information, which can be difficult to obtain, is often required from reporters; therefore, we developed targeted follow-up letters that we hoped would m...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.2165/11318940-000000000-00000
更新日期:2009-01-01 00:00:00
abstract::Cutaneous adverse drug reactions are a frequent occurrence and have been reported in more than 2% of hospitalised patients. Among the most commonly involved drugs are sulphonamides, penicillins, anticonvulsants and non-steroidal anti-inflammatory drugs. Two groups of mechanisms are involved in the pathogenesis of drug...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.2165/00002018-199005010-00005
更新日期:1990-01-01 00:00:00
abstract::Paraquat is a bipyridyl compound with no known chronic toxicity or teratogenicity. It is poorly absorbed when inhaled, but causes severe illness when ingested orally, death usually occurring within 2 days of ingestion of 50 mg/kg. At lower doses death may be delayed for several weeks. The toxic compound accumulates in...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.2165/00002018-199005040-00002
更新日期:1990-07-01 00:00:00
abstract::Aspirin (acetylsalicylic acid) and other nonsteroidal anti-inflammatory drugs (NSAIDs) cause deterioration in respiratory function in approximately 10% of adults with asthma and a smaller proportion of children with asthma. We propose evidence-based guidelines for the safe use of NSAIDs in individuals with asthma foll...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.2165/00002018-200124110-00004
更新日期:2001-01-01 00:00:00
abstract::The treatment of type 2 diabetes mellitus remains controversial. Since most patients are overweight or obese, regimens based on dietary modification and increased physical exercise are logical and safe treatment approaches. However, the long term impact of these interventions is frequently disappointing and pharmacoth...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.2165/00002018-199921010-00002
更新日期:1999-07-01 00:00:00
abstract:BACKGROUND:Screening large databases of spontaneous case reports of possible adverse drug reactions (ADRs) is an established method of identifying hitherto unknown adverse effects of medicinal products; however, there is a lack of consensus concerning the value of formal statistical screening procedures in guiding such...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.2165/11534410-000000000-00000
更新日期:2010-06-01 00:00:00
abstract::Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of certain forms of cancers, raising hopes for many patients with otherwise unresponsive tumours. While these agents are generally well tolerated, clinical experience with them has highlighted their unexpected association with serious toxic effects on...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.1007/s40264-013-0050-x
更新日期:2013-06-01 00:00:00
abstract:INTRODUCTION:Valbenazine is a novel vesicular monoamine transporter 2 inhibitor approved for the treatment of tardive dyskinesia in adults. OBJECTIVE:Using data from double-blind, placebo-controlled trials, analyses were conducted to evaluate the cardiovascular effects of once-daily valbenazine in patients with a psyc...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.1007/s40264-017-0623-1
更新日期:2018-04-01 00:00:00
abstract:INTRODUCTION:Real-world data on the comparative effectiveness and safety of switching among different epoetins (including originators and biosimilars) are limited. In light of current debate about interchangeability, prescribers, some patient groups and decision makers are calling for additional post-marketing evidence...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.1007/s40264-019-00845-y
更新日期:2019-12-01 00:00:00
abstract:INTRODUCTION:Although the mortality risk associated with tramadol use in children has triggered the revision of tramadol drug labeling, the mortality risk in adults has not been thoroughly explored. OBJECTIVE:The objective of this study was to evaluate whether tramadol use is associated with mortality in various risk ...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.1007/s40264-018-00786-y
更新日期:2019-06-01 00:00:00
abstract::Benzodiazepine drugs have been shown to suppress respiratory function in patients with chronic obstructive pulmonary disease (COPD). We designed a placebo-controlled crossover study to compare the effects of a new benzodiazepine, estazolam ('ProSom'), with those of flurazepam ('Dalmane') on cardiopulmonary function in...
journal_title:Drug safety
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00002018-199207020-00006
更新日期:1992-03-01 00:00:00
abstract::Absolute and functional iron deficiency is the most common cause of epoetin (recombinant human erythropoietin) hyporesponsiveness in renal failure patients. Diagnostic procedures for determining iron deficiency include measurement of serum iron levels, serum ferritin levels, saturation of transferrin and percentage of...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.2165/00002018-199717040-00004
更新日期:1997-10-01 00:00:00
abstract::Probiotics have seen widespread use for a variety of gastrointestinal problems, especially in two common disorders: irritable bowel syndrome and inflammatory bowel disease. Since a wide variety of probiotic preparations has been used, and despite a large number of studies performed, a great deal of heterogeneity exist...
journal_title:Drug safety
pub_type: 杂志文章,评审
doi:10.1007/s40264-015-0349-x
更新日期:2016-04-01 00:00:00
abstract:OBJECTIVE:Minocycline is an antibacterial drug used in the treatment of acne. Concern has been expressed over the possibility of severe adverse reactions to minocycline, including hepatitis. This study set out to identify and characterise reported cases of hepatotoxicity associated with the use of minocycline. METHODS...
journal_title:Drug safety
pub_type: 杂志文章
doi:10.2165/00002018-200023040-00006
更新日期:2000-10-01 00:00:00